XNASNRIX
Market cap1.29bUSD
Jan 10, Last price
18.24USD
1D
-6.51%
1Q
-22.81%
IPO
-6.80%
Name
Nurix Therapeutics Inc
Chart & Performance
P/E
—
P/S
16.78
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
27.53%
Rev. gr., 5y
15.50%
Revenues
77m
+99.31%
Net income
-144m
L-13.31%
CFO
-81m
L-49.09%
Earnings
Feb 13, 2025
Profile
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑11 | 2022‑11 | 2021‑11 | 2020‑11 | 2019‑11 | 2018‑11 | |
| Income | ||||||
Revenues | 76,987 99.31% | 38,627 29.84% | ||||
Cost of revenue | 421,198 | 233,302 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (344,211) | (194,675) | ||||
NOPBT Margin | ||||||
Operating Taxes | (14,315) | |||||
Tax Rate | ||||||
NOPAT | (344,211) | (180,360) | ||||
Net income | (143,948) -13.31% | (166,045) 41.68% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 3,217 | 117,192 | ||||
BB yield | -0.95% | -19.46% | ||||
| Debt | ||||||
Debt current | 13,906 | 5,530 | ||||
Long-term debt | 53,739 | 18,398 | ||||
Deferred revenue | 45,022 | 35,974 | ||||
Other long-term liabilities | (3,301) | |||||
Net debt | (227,684) | (349,092) | ||||
| Cash flow | ||||||
Cash from operating activities | (81,365) | (159,807) | ||||
CAPEX | (8,401) | (12,244) | ||||
Cash from investing activities | 68,301 | 27,198 | ||||
Cash from financing activities | 3,217 | 117,192 | ||||
FCF | (362,653) | (184,523) | ||||
| Balance | ||||||
Cash | 287,908 | 309,141 | ||||
Long term investments | 7,421 | 63,879 | ||||
Excess cash | 291,480 | 371,089 | ||||
Stockholders' equity | (545,806) | (405,524) | ||||
Invested Capital | 821,935 | 753,772 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 54,338 | 48,608 | ||||
Price | 6.22 -49.80% | 12.39 -57.01% | ||||
Market cap | 337,982 -43.88% | 602,253 -51.28% | ||||
EV | 110,298 | 253,161 | ||||
EBITDA | (330,557) | (183,867) | ||||
EV/EBITDA | ||||||
Interest | 14,315 | |||||
Interest/NOPBT | ||||||